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Rnd1Although Oct4 is known as a critical transcription factor involved in maintaining “stemness”, its role in tumor
metastasis is still controversial. Herein, we overexpressed and silenced Oct4 expression in two breast cancer
cell lines, MDA-MB-231 and 4T1, separately. Our data showed that ectopic overexpression of Oct4 suppressed
cell migration and invasion in vitro and the formation of metastatic lung nodules in vivo. Conversely, Oct4 down-
regulation increased themetastatic potential of breast cancer cells both in vitro and in vivo. Furthermore,we iden-
tiﬁed Rnd1 as the downstream target of Oct4 by ribonucleic acid sequencing (RNA-seq) analysis, which was
signiﬁcantly downregulated upon Oct4 overexpression. Chromatin immunoprecipitation assays revealed
the binding of Oct4 to the promoter region of Rnd1 by ectopic overexpression of Oct4. Dual luciferase assays
indicated that Oct4 overexpression suppressed transcriptional activity of the Rnd1 promoter. Moreover, overex-
pression of Rnd1 partially rescued the inhibitory effects of Oct4 on the migration and invasion of breast cancer
cells. Overexpression of Rnd1 counteracted the inﬂuence of Oct4 on the formation of cell adhesion and
lamellipodia, which implied a potential underlying mechanism involving Rnd1. In addition, we also found that
overexpression of Oct4 led to an elevation of E-cadherin expression, even in 4T1 cells that possess a relatively
high basal level of E-cadherin. Rnd1 overexpression impaired the promoting effects of Oct4 on E-cadherin
expression inMDA-MB-231 cells. These results suggest that Oct4 affects themetastatic potential of breast cancer
cells through Rnd1-mediated effects that inﬂuence cell motility and E-cadherin expression.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Metastasis remains intractable for the clinical treatment of breast
cancer, although signiﬁcant research progress has been made in recent
years [1]. Some studies have revealed that transcription factors related
to the maintenance of “stemness”, such as Sox-2 and c-Myc, are
involved in the regulation of metastasis [2,3]. Furthermore, a consider-
able number of studies have been carried out to investigate the relation-
ship between metastasis and Oct4, an essential transcription factor that
mediates thepluripotency of stem cells. So far, there is still no consensus
on the inﬂuence of Oct4 on tumormetastasis [4,5]. In human pancreatic
cancer, the expressional level of Oct4 was found negatively correlated
with the prognostic value of patients [6]. However, our previous study
showed that the downregulation of Oct4 increases the migration andgy, Medical School of Nankai
86 22 23504447; fax: +86 22invasion capabilities of MCF7 cells, a human breast cancer cell line
with a low metastatic potential [7]. Therefore, the role and underlying
mechanism of Oct4 in the metastasis of tumor is still far from clear.
Breast cancer metastasis is a multistep process involving numerous
genes [8]. Among them, loss of E-cadherin expression is a critical and
initial step for the occurrence of metastasis. E-cadherin is a transmem-
brane glycoprotein that is located in the adherent junctions of epithelial
cells [9]. It interacts with the cytoskeleton through associations with
cytoplasmic catenin proteins such as β-catenin, α-catenin, and p120
catenin (p120ctn) [10]. On the other hand, E-cadherin is also a regulator
of epithelial junction formation and appears to be necessary for cell–cell
adhesion [11]. In epithelial malignancy, the loss of E-cadherin plays a
vital role in the alteration of adhesive properties as well as epithelial-
to-mesenchymal transition, which are regarded as the key events for
metastasis. A decrease in the expression of E-cadherin has been widely
reported in the invasion of carcinomas, whereas increased expression of
E-cadherin correlates with reduced invasiveness [12]. E-cadherin
expression is regulated at both transcriptional and post-transcriptional
levels. Interestingly and in contrast to other induced pluripotent stem
Table 1
Primers for plasmids and polymerase chain reaction (PCR) assay.
Gene name Sequence (5′ → 3′)
Primers for plasmids
hOct4
Sense GCTCTAGAGCCACCATGGCGGGACACCTGGCTT
Antisense CGGGATCCTCAGTTTGAATGCATGGGAGAG
hRnd1
Sense GCTCTAGAGCCACCATGAAGGAGAGACGGGCCCCC
Antisense CGGGATCCTCACATAATGGAACAGCTTTTGGCCTT
mOct4
Sense GCTCTAGAGCCACCATGGCTGGACACCTGGCTTCAGA
Antisense GCTAGCTAGCTCAGTTTGAATGCATGGGAGAGCC
shRNA sequences for plasmids
mOct4-sh1 AAAAGGAGGAAGCCGACAACAATTTGGATCCAAATTGTTGTCGGCT
TCCTCC
mOct4-sh2 AAAAGAGCACGAGTGGAAAGCAATTGGATCCAAGCCTTAAGAACAT
GTGTAA
mOct4-sh3 AAAAGCCTTAAGAACATGTGTAATTGGATCCAATTACACATGTTCTTA
AGGC
hRND1-sh1 AAAAGCGAACAGACCTGAGTACTCTTTGGATCCAAAGAGTACTCAG
GTCTGTTCGC
hRND1-sh2 AAAAGGCCAGATGTAAGCTCGTTCTTTGGATCCAAAGAACGAGCTT
ACATCTGGCC
Scramble
Control
AAAAGCTACACTATCGAGCAATTTTGGATCCAAAATTGCTCGATAG
TGTAGC
qRT-PCR primers
Human Oct4
Sense TGAGGGCGAAGCAGGAGTC
Antisense GGAAAGGGACCGAGGAGTA
Human E-cadherin
Sense CTTCAATCCCACCACG
Antisense AAATGCCATCGTTGTTC
Human Rnd1
Sense TACGATAATGTCCGTCCACTC
Antisense CTTTGCTATTGCACAACCCT
Human GAPDH
Sense CGGGAAACTGTGGCGTGAT
Antisense AGTGGGTGTCGCTGTTGAAGT
ChIP assay primers
Sense CAAACACCCCTAAGCAGCTT
Antisense TAGCTGGGATTACAGGCATG
Dual luciferase assay
Sense CTAGCTAGCCACAAATCTCCAGGAGCCCTTAT
Antisense CCCAAGCTTCGTCTCAGCACGCCAATCAA
2088 L. Shen et al. / Biochimica et Biophysica Acta 1842 (2014) 2087–2095cell-related transcription factors, a study by Li et al. revealed that Oct4
possesses the unique capacity to suppress the EMT mediator Snail and
activate the epithelial program including inducing E-cadherin [13].
Rnd1 belongs to a unique subfamily of RhoGTPases and is associated
with ﬁve other GTPases: Rnd2, Rnd3, RhoH, RhoBTB1, and RhoBTB2.
These GTPases bind to GTP but do not show any detectable hydrolyza-
tion. Rnd1 and Rnd3 are involved in the regulation of E-cadherin and
the rearrangement of the cytoskeleton [14,15]. The expression of Rnd1
or Rnd3 is accompanied by the loss of actin stress ﬁbers [16,17], which
reduces cadherin-based cell–cell adhesion. Rnd3 can be downregulated
by Nanog, thus suppressing cell migration [18]. In addition, overexpres-
sion of Rnd3 downregulates the expression of E-cadherin in gastric
cancer cells [14]. Rnd1 affects cell morphologymainly through an inter-
action with p190RhoGAP and increase in the GTPase-activating protein
(GAP) activity of RhoA, thereby reducing RhoA-GTP levels [19,20].
RhoA-GTP levels correlate with E-cadherin expression [21]. Moreover,
RhoA functions as a regulator of cadherin-based cell–cell adhesion
that has a central role in themaintenance of cell adhesion in the epithe-
lium [22]. Upon activation, RhoA increases the accumulation of actin
ﬁlaments and adhesion of cadherin to cell walls [23].
In this study, we aimed to elucidate the role and underlying mecha-
nism of Oct4 in breast cancer metastasis. We also investigated whether
Rnd1 expression is regulated by Oct4 and its role in cadherin-based
cell–cell adhesion and tumor invasion. Our results provide novel
insights for the development of therapeutics targeting Oct4.
2. Material and methods
2.1. Cell lines and lentivirus production
4T1 cellswerepurchased from theCell Culture Center of the Shanghai
Institute for Biological Sciences (Chinese Academy of Science, Shanghai,
China) and cultured in RPMI 1640 supplemented with 10% fetal bovine
serum (FBS). T47D, MCF7, 4TO7 and EMT6 cells were obtained from
the American Type Culture Collection (Manassas, VA). MDA-MB-231
and 293T cells were kind gifts from Dr. Ralph Reisfeld (Scripps Research
Institute, La Jolla, CA) and cultured in Dulbecco's modiﬁed Eagle's
medium supplemented with 10% FBS. 293T cells were used to produce
lentiviruses for stable transfection of cell lines. Brieﬂy, 293T cells were
seeded in six-well plates (1 × 106 cells/well) and then transfected with
pLV-cDNA or pLV-shRNA together with VSV-G, Rev, and Gag-Pol
vectors by Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 16 h,
the transfection solutions were exchanged with fresh medium.
The culture supernatants containing viruses were collected after 40 h.
A total of 1 × 105 MDA-MB-231 or 4T1 cells in 2 ml medium with
8 μg/ml polybrene were infected with 1 ml lentivirus-containing
supernatant by centrifugation at 1100 g for 1 h. After 48 h of culture,
the cells were transferred to fresh medium containing blasticidin or
puromycin for selection. Control cell lines containing the empty
vector control or scrambled shRNA (sc) were established by the
same method.
2.2. Plasmids
To construct human OCT4, mouse Oct4, and human RND1 overex-
pression vectors, human or mouse cDNAs were ampliﬁed by PCR
and then cloned into pLV-EF1-MCS-IRES-Bsd (Biosettia, San Diego,
CA). To silence mouse Oct4, three shRNAs were designed by the online
application at the Invitrogen website (https://rnaidesigner.invitrogen.
com/rnaiexpress/index.jsp). To silence human RND1, we designed
two shRNAs using the same website. A scrambled sequence was
used as a control for knockdown analysis. The shRNAs were cloned
into pLV-H1-EF1α-puro vector (Biosettia) to generate pLV-shRNA
plasmids. The primers and shRNA sequences are summarized in
Table 1.2.3. Migration, invasion, and wound healing assays
Cell migration and invasion assays were performed as described
previously [7]. For migration assays, 1 × 105 MDA-MB-231 or 5 × 104
4T1 cells were re-suspended in serum-free medium and seeded into
Boyden chamber inserts with an 8-μm pore membrane (BD Bioscience,
Franklin Lakes, NJ). Medium containing 10% FBSwas added to the lower
chamber. For invasion assays, the upper chamber of the insert was coat-
edwithMatrigel (BD Biosciences), and 1 × 106MDA-MB-231 or 5 × 105
4T1 cells were added to the inserts. For wound healing assays, 1 × 106
MDA-MB-231 or 3 × 105 4T1 cells were seeded and grown to 90%
conﬂuence. A sterile pipette tipwas then used to create scratchwounds.
Images were then taken at 0, 24 and 48 h with an IX71 inverted micro-
scope (Olympus, Tokyo, Japan). Three independent experiments were
performed.
2.4. Adhesion assays
96-well plates were coated with 50 μl/well collagen I (sc-136154,
Santa Cruz Biotechnology, Santa Cruz, CA). MDA-MB-231 cells were
detached with 10 mM ethylene diamine tetraacetic acid/PBS
(phosphate-buffered saline) and dispersed as single cells. A cell suspen-
sion of 2 × 105 cells/ml (100 μl)was added to eachwell. After incubation
2089L. Shen et al. / Biochimica et Biophysica Acta 1842 (2014) 2087–2095for 60min at 37 °C, the unattached cells were removed bywashingwith
PBS. The attached cells were ﬁxed with 4% formaldehyde and then
stained with crystal violet. Each condition was evaluated in quadrupli-
cate. Attached cells were counted under a 20× objective.
2.5. Animal models of tumors
6- to 8-week-old female NOD/SCID and BABL/c mice were pur-
chased from Beijing HFK Bio-Technology (Peking, China). Experiments
were conducted according to Nankai University Guidelines for Animal
Experiments. Mice were anaesthetized with 7% trichloroacetaldehyde
hydrate before injection. To establish tumors using MDA-MB-231
cells, 100 μl of 3 × 107 cells/ml was injected into the fourth fat pad of
NOD/SCID mice. To establish 4T1 tumors, mice were divided randomly
into ﬁve groups (n = 5): vector control-overexpressing, Oct4-
overexpressing, scrambled control, Oct4 shRNA-2 and Oct4 shRNA-3.
Stably transfected 4T1 cells (1 × 105) were injected into the fourth fat
pad of BABL/c mice. Mice were sacriﬁced at day 30 after injection.
Primary tumors and lungs were separated for tissue sectioning and
homogenate preparation.
2.6. Tissue processing, hematoxylin and eosin staining, and
immunohistochemistry
Tumor tissues and lungs were ﬁxed with paraformaldehyde,
embedded in parafﬁn, and then sectioned. Some sections were incu-
bated with hematoxylin and eosin (H&E), dehydrated, and mounted.
For E-cadherin or RND1 staining, sections were incubated at 4 °C over-
night with anti-E-cadherin (610182, BD Biosciences) or -RND1
(sc-25029, Santa Cruz Biotechnology) antibodies. After incubation
with a biotinylated secondary antibody for 90 min and then an
avidin–peroxidase complex for 30 min, the sections were visualized
with DAB or AEC and counterstained with hematoxylin. Images were
obtained with a BX53 research microscope (Olympus).
2.7. RNA extraction, PCR, and RNA-seq analysis
Total RNA was extracted using a TRIzol reagent [24]. Products of
semi-quantitative PCR were detected by agarose gel electrophoresis.
The primers used are listed in Table 1. For RNA-seq analysis, 1 × 107
Oct4-overexpressing or control MDA-MB-231 cells were collected to
extract total RNA. mRNA was puriﬁed by Oligo(dT) magnetic bead
adsorption. Transcription data were proﬁled and compared according
to standard protocols (digital gene expression, Beijing Genomics
Institute, Beijing, China).
2.8. Protein isolation and Western blotting
Cell lysates were prepared with cold radioimmunoprecipitation
assay lysis buffer as described previously [25]. Equivalent total protein
from each lysate was loaded onto 10–12% Tris–acrylamide gels, electro-
phoresed, and then transferred to nitrocellulose membranes. After
blocking nonspeciﬁc binding sites, the membranes were probed with
primary antibodies, including anti-Oct4 (sc-25029), anti-Rnd1
(sc-5279, Santa Cruz Biotechnology), anti-E-cadherin (610182, BD Bio-
sciences), and then horseradish peroxidase-conjugated secondary anti-
bodies. Labeled proteins were detected by an ECL chemiluminescence
kit (Millipore, Billerica, MA).
2.9. Immunoﬂuorescence and cytoskeleton staining
E-cadherin was detected by immunoﬂuorescence [7] using an
antibody against E-cadherin (610182, BD Biosciences). For cytoskeleton
staining, cells were ﬁxed with 4% formaldehyde for 15 min and then
blocked with 1% bovine serum albumin for 1 h. After rinsing, the cells
were incubated with 5 μg/ml FITC-phalloidin (P2141, Sigma, St. Louis,MO) at room temperature for 1 h. The lamellipodia of each cell was
counted to represent the cell morphology after gene expression
changes. Images were obtained with a FV10000 confocal microscope
(Olympus).
2.10. Chromatin immunoprecipitation (ChIP) assay
ChIP assayswere performed using an EZ-ChIP kit (Millipore) follow-
ing the manufacturer's instructions. In brief, cells grown in 100-mm
dishes were cross-linked with 1% formaldehyde for 10 min at room
temperature. The reaction was stopped by the addition of 1 ml glycine.
Fixed cells were washed twice and then transferred into a 1.5-ml
centrifuge tube. After centrifugation, the cell pellet was resuspended
in 1ml SDS lysis buffer. About 1 × 106 cells were used for each immuno-
precipitation by using antibody agaist Oct4 (2750, Cell Signal Technolo-
gy, Danvers, MA). Semi-quantitative RT-PCR was performed using
TransStart FastPfu DNA Polymerase (TransGen Biotech, Peking, China).
Chromatin binding was compared with the amount of input.
2.11. Dual luciferase assay
The human RND1 promoter predicted by software was cloned
downstream of the ﬁreﬂy luciferase (FL) coding region into a
pGL3-basic luciferase reporter vector (Promega, Madison, WI). Cells
were co-transfected with pGL3-Rnd1 promoter and pLV-control or
pLV-hOct4 plasmids. A pRL Renilla luciferase (RL) reporter vector
(pRL-TK) was used as the internal control. At 48 h after transfection,
cell lysates were collected and the activation of the RND1 promoter
wasquantiﬁed as the ratio of FL/RL activity following themanufacturer's
instructions.
2.12. Statistical analysis
Data analysis was performed using the GraphPad Prism 5 software.
All results are presented as themean± S.E.M. The differences between
two groupswere analyzed by two-way analysis of variance. A P-value of
less than 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Oct4 expression levels affect the metastatic potential of breast cancer
cells
To determine the effect of Oct4 on the metastasis of breast cancer,
we ﬁrst detected the basal expression level of Oct4 in a variety of
human and mouse breast cancer cell lines with different metastatic
potentials (Fig. 1A). Comparing with the relatively low metastatic
efﬁcient cell lines, MDA-MB-231 and 4T1 exert a lower Oct4 expression
level. We then established stable Oct4-overexpressing MDA-MB-231
and 4T1 cell lines, as well as a stable Oct4-silenced 4T1 cell line. Results
of wound healing and transwell assays suggested that exogenous over-
expression of Oct4 suppressed the migration and invasion capacities of
MDA-MB-231 and 4T1 cells (Fig. 1B–D), whereas the downregulation of
Oct4 increased the migration of 4T1 cells (Fig. 1G & H). Consistent with
the results of in vitro experiments, therewere signiﬁcantly lessmetasta-
tic lung nodules in mice injected with Oct4-overexpressing MDA-MB-
231 or 4T1 cells compared with those in the controls (Fig. 1E). Further-
more, there were more metastatic lung nodules in mice injected with
Oct4-silenced 4T1 cells compared with those in the control (Fig. 1I).
However, no detectable difference in tumor initiation and growth
could be found between Oct4-overexpressing or Oct-silenced groups
with their respective control (Fig. 1F & H). Combined with our previous
data showing that the downregulation of Oct4 increases the migration
and invasion capabilities of MCF7 cells, our in vivo and in vitro experi-
mental data here suggested that the exogenous overexpression of
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Fig. 1. Oct4 expression levels inﬂuence the metastatic potential of breast cancer cells. We compared the expression level of Oct4 in a variety of breast cancer cell lines with different
metastatic potentials. (A) The results of Western blotting by using an antibody against Oct4. We established stable Oct4-overexpressing MDA-MB-231 and 4T1 cell lines as well as
their respective stable vector control-overexpressing cell lines. (B & C) Representative images of the wound healing assay and statistic results on the migrated distances are shown.
***P b 0.001. (D) Results of invasion assays. Data represent the mean ± S.E.M. of triplicate wells. *P b 0.05, **P b 0.01. A total of 3 × 106 Oct4-overexpressing or control MDA-MB-231
cells were injected into the fat pad of 6–8-week-old NOD/SCID mice (n = 5). Primary tumors and lungs were isolated at day 56 after injection. In addition, 1 × 105 Oct4-
overexpressing or control 4T1 cells were injected into the fat pad of 6–8-week-old Balb/c mice (n = 5). Primary tumors and lungs were isolated at day 30 after injection.
(E) Representative images of H&E staining and the number of metastatic nodules in the lungs are shown. Scale bar = 20 μm. Data represent the mean ± S.E.M. *P b 0.05, **P b 0.01.
Tumor growth curves are shown in (F). 4T1 cells were stably transfected with scrambled shRNA (sc) or Oct4 shRNAs (sh1, sh2, or sh3). (G) Western blotting was used to detect the
efﬁciency of Oct4 silencing in the stably transfected cell lines. (H) Migrated cell counts in the transwell assay. Data represent the mean ± S.E.M. of triplicate wells. *P b 0.05, **P b 0.01.
A total of 1 × 105 4T1-sc, 4T1- sh2, or 4T1-sh3 cells were injected into the fat pad of 6–8-week-old Balb/cmice (n=5). Primary tumors and lungswere isolated at day 30 after inoculation.
(I) Representative images of H&E staining of the lungs and the numbers of metastatic lung nodules are shown. Scale bar = 50 μm, *P b 0.05. Tumor growth curves are shown in (J).
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increased the metastatic potential of breast cancer cells.
3.2. Overexpression of Oct4 suppresses Rnd1 transcription in breast cancer
cells
To investigate the mechanism underlying the role of Oct4 in
breast cancer metastasis, we performed RNA-seq analyses of Oct4-FAM180A
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ly, the downregulation of Oct4 increased Rnd1 expression in 4T1
cells (Fig. 2E). Furthermore, Rnd1 expression levels were higher in
SK-BR-3 and MDA-MB-231 cells compared with that in the cell
lines with a relatively low metastatic potential (Fig. 2F). The results
of ChIP assays indicated a binding site for Oct4 in the promoter
region of Rnd1 (Fig. 2G). Upon the overexpression of Oct4, luciferase
activity was impaired in cells transfected with a plasmid containing
the Rnd1 promoter (Fig. 2H). In vivo, Western blotting showed
that the Rnd1 level in tumor tissue homogenates of the Oct4-
overexpressing group was signiﬁcantly lower than that in the
control group (Fig. 2I and J). All these data indicate that theBA
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3.3. Suppression of Rnd1 partially contributes to the inhibitory effect of Oct4
overexpression on the metastasis of MDA-MB-231 cells
Rnd1 is a member of the Rho GTPase family and involved in the
regulation of cell motility. Considering the signiﬁcant inhibitory effect
of Oct4 on Rnd1 expression as well as the essential role of cell motility
regulation in the metastatic process, we hypothesized that Rnd1
might mediate the effects of Oct4 on metastasis. First, we examined
the effects of Rnd1 in MDA-MB-231 cells. Transwell assays revealed0
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and invasion capacities of MDA-MB-231 cells (Fig. 3A). Furthermore,
Rnd1 overexpression partially rescued the migration and invasion
defects induced byOct4 (Fig. 3B). Immunoﬂuorescence staining showed
that overexpression of Oct4 increased the formation of lamellipodia in
MDA-MB-231 cells, whereas this effect was partially reversed by the
overexpression of Rnd1 (Fig. 3C and D). In addition, increased adhesion
to the extracellular matrix protein collagen I, which was induced by the
overexpression of Oct4, was also partially rescued by Rnd1 overexpres-
sion (Fig. 3E). These data suggest that Rnd1 mediates the effect of Oct4
on metastasis by inﬂuencing the lamellipodia formation as well as cell
adhesion.
3.4. Expression levels of Oct4 affect E-cadherin expression in breast cancer
cells
Our previous study showed that the downregulation of Oct4
suppresses the expression of E-cadherin in MCF7 cells. To further
conﬁrm the inﬂuence of Oct4 on E-cadherin expression, we examined
the expression level of E-cadherin in stable Oct-overexpressing MDA-
MB-231 and 4T1 cell lines. Western blotting showed that the ectopic
overexpression of Oct4 induced E-cadherin expression in both cell
lines compared with that in their control cells (Fig. 4A and B).
E-cadherin expression at cell–cell junctions was signiﬁcantly enhanced
in Oct4-overexpressing cells compared with that in control cellsE
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basal level of E-cadherin, the expression of E-cadherinwas still elevated
by 55.8% in cells overexpressing Oct4 (Fig. 4D). The expression of
E-cadherin was compared in tumor tissues from mice injected with
Oct4-overexpressing or control MDA-MB-231 cells. RT-PCR and
Western blotting showed higher E-cadherin expression in the Oct4-
overexpressing group at both mRNA and protein levels (Fig. 4E).
Accordingly, the downregulation of Oct4 led to the suppression of
E-cadherin expression in not only cultured 4T1 cells but also in tumor
tissues from mice injected with Oct4-silenced 4T1 cells (Fig. 4F and G).3.5. Rnd1 mediates the suppression of E-cadherin induced by Oct4 in
MDA-MB-231 cells
To determine whether the inﬂuence of Oct4 on Rnd1 plays a role in
the regulation of E-cadherin expression by Oct4, we ﬁrst detected the
expression level of E-cadherin in Rnd1-silenced MDA-MB-231 cells. It
is clear that 231-sh2 can effectively knockdown the expression of
Rnd1 in MDA-MB-231 cells. The results showed the signiﬁcantly sup-
pressed expression of E-cadherin (Fig. 5A). Moreover, Western blotting
and immunoﬂuorescence showed that Rnd1 rescued the increase of
E-cadherin caused by the overexpression of Oct4 (Fig. 5B and C).
These data suggest that Rnd1 mediates the regulatory effect of Oct4
on E-cadherin in MDA-MB-231 cells.-cadherin DAPI Overlay
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Oct4 is well known for its key role in the maintenance of self-
renewal and pluripotency, the central features of embryonic stem
cells. Recent studies indicate that some tumor cells also possess stem
cell-like properties [26]. Moreover, Oct4 is regarded as a marker of
these stem-like cells in cancers. Although several studies have tried to
establish a link between Oct4 and the malignant potential of cancer
cells [27], the exact role of Oct4 in tumor metastasis and its underlying
mechanism are still unclear. Our previous study demonstrated that the
downregulation of Oct4 in MCF7 cells suppresses E-cadherin expres-
sion, thus promoting their migration and invasion. However, consider-
ing the heterogeneity of breast cancer cells, especially in terms of
metastatic characteristics, a more thorough and detailed study appears
to be necessary. To further evaluate the role of Oct4 in themetastasis of
breast cancer, we chose two breast cancer cell lineswith highmetastatic
potentials, MDA-MB-231 and 4T1. Our data showed that basal levels of
Oct4 expression in MDA-MB-231 and 4T1 cells were relatively lower
than that in the breast cancer cells with a low potential for metastasis.
The ectopic expression of Oct4 in MDA-MB-231 and 4T1 breast cancer
cells suppressed cellmigration and invasion in vitro aswell asmetastatic
lung nodules in vivo. No signiﬁcant differences were found in the tumor
volume and weight by altering the Oct4 expression levels. Therefore,
our data suggest that the expression of Oct4 affects the metastatic
potential of breast cancer cells.
In this study, RNA-seq analysis revealed that the ectopic expression
of Oct4 led to a dramatic decrease of Rnd1 expression. ChIP assay
showed that Oct4 directly bound to the promoter of Rnd1, thus inducing
the suppression of Rnd1 expression inMDA-MB-231 cells. Ectopic Rnd1
overexpression increased the migration and invasion capacities of
MDA-MB-231 cells. In addition, Rnd1 partially compensated for the
impaired migration and invasion caused by Oct4 overexpression. As a
member of the RhoGTPase family, Rnd1 has been previously reported
to participate in the regulation of cellular motility. Recent studies
have revealed that Rnd1 binds to and activates p190RhoGAP, and then
antagonizes RhoA/ROCK-induced myosin light chain phosphorylation
and actomyosin contractility to regulate cell motility [28]. On the
other hand, Rnd1 also binds to plexins and activates their R-Ras GAP
domain, resulting in actin rearrangement that reduces integrin-
mediated cell adhesion. Therefore, by regulating the actin cytoskeleton,
Rnd1 promotes the loss of actin stress ﬁbers and the formation of focaladhesions, resulting in an increase of cell migration. Our data showed
that ectopic Rnd1 suppressed the adhesion capacity of MDA-MB-231
cells. Also, it partially reduced the increased adhesion in the stable
Oct4-overexpressing cells. To our surprise, the overexpression of Oct4
prompted the increased formation of lamellipodia, which was partially
counteracted by the overexpression of Rnd1. The results seem likely at
odd with the anti-metastatic effect of ectopic Oct4 expression since
the formation of lamellipodia is conventionally thought as a facilitator
of cell locomotion [29]. We consider that it might be a reﬂection of the
complexity of RhoGTPase regulation. It has been reported that cell adhe-
sion and the formation of lamellipodia were regulated via distinct
RhoGTPase signals [30]. RhoA regulates cytoskeletal changes affecting
cell adhesion while Rac1 majorly mediates lamellipodia formation.
Nevertheless, there exists a crosslink between the two signaling path-
ways. Sander et al. showed that Rac1 exerts an inhibitory function on
RhoA activity by inducing the reactive oxygen species [31]. Considering
the sophistication of tumor metastasis, it is not hard to speculate that
Oct4 inﬂuences the metastasis via diverse mechanisms although the
role of Rnd1 in mediating lamellipodia formation remains unsolved.
Loss of cell–cell adhesion is a requirement for the invasion of epithe-
lial tumors whether it occurs in a single cell or a multicellular unit [32].
As an epithelialmarker associatedwith cell–cell junctions and adhesion,
the loss of E-cadherin is the initial step and a driving force for epithelial-
to-mesenchymal transition (EMT) that plays a critical role in tumor
progression. Our data demonstrated that ectopic overexpression of
Oct4 upregulated the expression of E-cadherin, even in 4T1 cells
which basally express E-cadherin at an extremely high level. This result
is consistent with the observation that Oct4 is a potent inducer of
mesenchymal-to-epithelial transition (MET) in the induced pluripotent
stem cell-related study [13]. Interestingly, silencing Rnd1 increased the
expression of E-cadherin and the overexpression of Rnd1 partly
inhibited the upregulation of E-cadherin induced by Oct4 in MDA-
MB-231 cells. Recent studies have indicated that E-cadherin expression
is correlated with the activities of RhoGTPases. Reynolds et al. reported
that E-cadherin affects RhoA activity through its binding partner
p120ctn [33]. p120ctn binds directly to E-cadherin and also inhibits
RhoA activity by a direct interaction with p190RhoGEF. Thus,
E-cadherin competes with p190RhoGEF for interactions with p120ctn
in a cell density-dependent manner [34]. Consequently, high
E-cadherin expression leads to a potent activation of RhoA. Meanwhile,
p120ctn also promotes Rac1 activity and induces the formation of a
2095L. Shen et al. / Biochimica et Biophysica Acta 1842 (2014) 2087–2095motile, protrusive membrane structure, such as lamellipodia [35].
These might explain why Rnd1, via the suppression of E-cadherin,
exerts inﬂuence on the formation of lamellipodia as we mentioned
above. Obviously, more convincing evidence is still needed to prove
this hypothesis. Our ﬁnding that Rnd1 mediates the effect of Oct4
on E-cadherin expression sheds light on the mechanism in tumor
metastasis.
In conclusion, our results demonstrate that the Oct4 expression level
exerts regulatory effects on the metastasis of breast cancer cells. The
underlying mechanism may involve Oct4 regulating the expression of
Rnd1, which in turn inﬂuences E-cadherin expression as well as
cytoskeleton rearrangement. Therefore, our ﬁndings may provide a
novel potential strategy for the treatment of breast cancer metastasis.
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